<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kairos Pharma, Ltd. — News on 6ix</title>
<link>https://6ix.com/company/kairos-pharma-ltd</link>
<description>Latest news and press releases for Kairos Pharma, Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kairos-pharma-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d761c451cc36e475339df7.webp</url>
<title>Kairos Pharma, Ltd.</title>
<link>https://6ix.com/company/kairos-pharma-ltd</link>
</image>
<item>
<title>Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-recognized-with-pinnacle-award-for-excellence-in-healthcare-innovation</guid>
<pubDate>Wed, 15 Apr 2026 13:00:00 GMT</pubDate>
<description>LOS ANGELES, April 15, 2026--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the 2026 Pinnacle Awards for Healthcare, being selected as an Emerald honoree for Innovator of Biotech Solutions for addressing cancer drug resistance.</description>
</item>
<item>
<title>Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-signing-of-binding-strategic-asset-acquisition-of-exclusive-worldwide-rights-to-cl-273-from-orbimed-and-torrey-pines-investment-backed-celyn-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-signing-of-binding-strategic-asset-acquisition-of-exclusive-worldwide-rights-to-cl-273-from-orbimed-and-torrey-pines-investment-backed-celyn-therapeutics</guid>
<pubDate>Mon, 02 Mar 2026 11:30:00 GMT</pubDate>
<description>LOS ANGELES, March 02, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.</description>
</item>
<item>
<title>Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-signing-of-term-sheet-for-strategic-asset-acquisition-of-two-clinical-oncology-assets-from-celyn-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-signing-of-term-sheet-for-strategic-asset-acquisition-of-two-clinical-oncology-assets-from-celyn-therapeutics</guid>
<pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
<description>LOS ANGELES, February 26, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. Under the proposed terms of the agreement, Kairos Pharma will acquire worldwide rights to two highly differentiated, clinical-stage oncology ass</description>
</item>
<item>
<title>Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-at-3rd-annual-dealflow-discovery-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-at-3rd-annual-dealflow-discovery-conference</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>LOS ANGELES, January 20, 2026--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it will participate in the DealFlow Discovery Conference, taking place Jan. 28-29, 2026, at the Borgata Hotel in Atlantic City, NJ. Kairos Pharma Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event.</description>
</item>
<item>
<title>Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-wins-2025-clinical-trials-arena-research-and-development-excellence-award-for-advanced-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-wins-2025-clinical-trials-arena-research-and-development-excellence-award-for-advanced-prostate-cancer</guid>
<pubDate>Wed, 17 Dec 2025 13:15:00 GMT</pubDate>
<description>LOS ANGELES, December 17, 2025--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer.</description>
</item>
<item>
<title>Kairos Pharma Provides Shareholder Update</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-provides-shareholder-update</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-provides-shareholder-update</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>LOS ANGELES, November 04, 2025--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below.</description>
</item>
<item>
<title>Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-presents-on-phase-2-trial-of-env-105-in-advanced-prostate-cancer-at-european-society-medical-oncologists-esmo-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-presents-on-phase-2-trial-of-env-105-in-advanced-prostate-cancer-at-european-society-medical-oncologists-esmo-meeting</guid>
<pubDate>Mon, 20 Oct 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, October 20, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society Medical Oncologists meeting in Berlin, Germany.</description>
</item>
<item>
<title>Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-positive-safety-and-efficacy-data-from-phase-2-prostate-cancer-trial-at-esmo-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-positive-safety-and-efficacy-data-from-phase-2-prostate-cancer-trial-at-esmo-2025</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, October 07, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cancer therapeutics, today announced that it has been selected to present at the European Society for Medical Oncology (ESMO) Congress. Kairos’s presentation, titled, "Preliminary safety and clinical activity from a Phase 2 study of apalutamide and carotuximab in advanced, castration-resistant prostate cancer" will take place in Berlin</description>
</item>
<item>
<title>Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-positive-interim-efficacy-analysis-of-phase-2-trial-of-env105-in-advanced-prostate-cancer-with-median-progression-free-survival-of-over-one-year</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-positive-interim-efficacy-analysis-of-phase-2-trial-of-env105-in-advanced-prostate-cancer-with-median-progression-free-survival-of-over-one-year</guid>
<pubDate>Thu, 18 Sep 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, September 18, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Kairos Pharma is hosting a virtual KOL (key opinion leader) event to provide perspectives on this data at 5 p.m. ET / 2 p.m. PT today. Interested participants ca</description>
</item>
<item>
<title>Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-virtual-kol-event-to-provide-perspectives-on-env105-interim-efficacy-results-in-advanced-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-virtual-kol-event-to-provide-perspectives-on-env105-interim-efficacy-results-in-advanced-prostate-cancer</guid>
<pubDate>Thu, 11 Sep 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, September 11, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Intere</description>
</item>
<item>
<title>Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-presentation-of-new-phase-1-data-on-env105-combination-therapy-in-non-small-cell-lung-cancer-at-the-world-lung-cancer-conference-september-6-9-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-presentation-of-new-phase-1-data-on-env105-combination-therapy-in-non-small-cell-lung-cancer-at-the-world-lung-cancer-conference-september-6-9-2025</guid>
<pubDate>Wed, 03 Sep 2025 12:15:00 GMT</pubDate>
<description>LOS ANGELES, September 03, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.</description>
</item>
<item>
<title>Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>LOS ANGELES, September 02, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.</description>
</item>
<item>
<title>Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-participation-and-presentation-in-the-hc-wainwright-27th-annual-global-investment-conference-september-8-10-2025</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-participation-and-presentation-in-the-hc-wainwright-27th-annual-global-investment-conference-september-8-10-2025</guid>
<pubDate>Wed, 16 Jul 2025 12:30:00 GMT</pubDate>
<description>LOS ANGELES, July 16, 2025--Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. Kairos Pharma will participate in on-on-one meetings and present at the meeting which will be available virtually and hosted on the kairospharma</description>
</item>
<item>
<title>Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-positive-safety-results-from-phase-2-trial-of-env-105-in-advanced-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-announces-positive-safety-results-from-phase-2-trial-of-env-105-in-advanced-prostate-cancer</guid>
<pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, July 15, 2025--Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone</description>
</item>
<item>
<title>Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-new-data-on-small-molecule-gitr-ligand-agonist-kros-101-as-promising-cancer-immunotherapy-at-the-american-society-of-clinical-oncology-asco-2025-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-new-data-on-small-molecule-gitr-ligand-agonist-kros-101-as-promising-cancer-immunotherapy-at-the-american-society-of-clinical-oncology-asco-2025-annual-meeting</guid>
<pubDate>Tue, 03 Jun 2025 12:15:00 GMT</pubDate>
<description>LOS ANGELES, June 03, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill.</description>
</item>
<item>
<title>Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-participation-in-the-d-boral-capital-inaugural-global-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-participation-in-the-d-boral-capital-inaugural-global-conference</guid>
<pubDate>Tue, 06 May 2025 12:00:00 GMT</pubDate>
<description>Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.John Yu, MD, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET). To register for one-on-one meetings with management at The Plaza Hotel ...</description>
</item>
<item>
<title>Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-data-to-be-presented-at-the-american-society-of-clinical-oncology-asco-2025-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-announces-data-to-be-presented-at-the-american-society-of-clinical-oncology-asco-2025-annual-meeting</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, April 28, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill.</description>
</item>
<item>
<title>Kairos Pharma Ltd. Provides Letter to Stockholders</title>
<link>https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-provides-letter-to-stockholders</link>
<guid isPermaLink="true">https://6ix.com/company/kairos-pharma-ltd/news/kairos-pharma-ltd-provides-letter-to-stockholders</guid>
<pubDate>Thu, 24 Apr 2025 12:00:00 GMT</pubDate>
<description>LOS ANGELES, April 24, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.:</description>
</item>
</channel>
</rss>